文献速递免疫规划

15价肺炎球菌结合疫苗在未接种过肺炎球菌疫苗的≥50岁成人中的安全性和免疫原性

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age.
PubMed 文献 · Vaccine · 2018-03-17

691名≥50岁未接种过肺炎球菌疫苗的成人随机接种一剂PCV15、PCV13或PPV23,随访14天评估安全性,并检测接种前和接种后1个月的血清型特异性IgG GMC和OPA GMT。PCV15安全性与其他两组相当,对共有血清型的免疫应答与PCV13和PPV23相当,对PCV15独有血清型(22F、33F及PPV23不含的6A)诱导更高的IgG和OPA抗体。

要点

  • PCV15在≥50岁未接种肺炎球菌疫苗成人中安全性可接受。
  • 对共有血清型,PCV15诱导的IgG GMC和OPA GMT与PCV13和PPV23相当。
  • 对PCV15独有血清型22F、33F及PPV23不含的6A,PCV15诱导的IgG和OPA抗体高于对照疫苗。

核心结论

  • PCV15安全性可接受,对疫苗包含的全部15个血清型均诱导IgG和OPA抗体,对共有血清型的水平与PCV13和PPV23相当。

研究设计与样本

  • 691名≥50岁未接种过肺炎球菌疫苗的成人接种一剂PCV15、PCV13或PPV23,随访14天评估安全性(NCT01513551)。

主要发现

  • 各疫苗接种组安全性特征相当。
  • 对共有血清型,PCV15诱导的IgG GMC和OPA GMT与PCV13和PPV23相当。
  • PCV15受种者血清型特异性抗体数值上高于PCV13受种者的共有血清型有7个,高于PPV23受种者的有12个;低于PCV13和PPV23受种者的分别有4个和1个血清型。
  • 对PCV15独有血清型(22F和33F不在PCV13中;6A不在PPV23中),PCV15诱导的IgG和OPA抗体高于PCV13或PPV23。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pneumococcal disease remains a public health priority in adults. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) containing 13 serotypes included in 13-valent pneumococcal conjugate vaccine (PCV13) plus 2 additional serotypes (22F and 33F) was evaluated in adults ≥50 years old (NCT01513551). METHODS: 691 adults received one dose of PCV15, PCV13, or 23-valent pneumococcal polysaccharide vaccine (PPV23) and were followed 14 days for safety. Serotype-specific IgG geometric mean concentrations (GMCs) and opsonophagocytic activity (OPA) geometric mean titers (GMTs) were measured immediately prior and 1-month postvaccination. RESULTS: Safety profiles were comparable across vaccination groups. PCV15 induced comparable levels of IgG GMCs and OPA GMTs to PCV13 and PPV23 for shared serotypes. Serotype-specific antibodies were numerically higher among recipients of PCV15 than PCV13 and PPV23 for 7 and 12 shared serotypes, respectively; and lower for 4 and 1 serotype(s), respectively. PCV15 induced higher IgG and OPA antibodies than PCV13 or PPV23 for serotypes unique to PCV15 (22F and 33F not in PCV13; 6A not in PPV23). CONCLUSIONS: PCV15 displayed an acceptable safety profile and induced IgG and OPA to all 15 serotypes included in the vaccine, at levels comparable to PCV13 and PPV23 for shared serotypes with these vaccines. Study identification: V114-002. CLINICALTRIALS.GOV identifier: NCT01513551. © 2018 Merck & Co., Inc.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ermlich SJ, Andrews CP, Folkerth S, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age. Vaccine. 2018. PMID: 29559167. doi:10.1016/j.vaccine.2018.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。